d-alpha tocopherol has been researched along with rhodanine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Azuma, K; Fujitani, Y; Hirose, T; Ikeda, F; Kanazawa, A; Kawamori, R; Ohmura, C; Shimizu, T; Tanaka, Y; Watada, H; Yoshihara, T | 1 |
| Banala, VT; Dwivedi, M; Gautam, S; Marwaha, D; Mishra, PR; Sharma, M; Sharma, S; Shukla, RP; Urandur, S | 1 |
1 trial(s) available for d-alpha tocopherol and rhodanine
| Article | Year |
|---|---|
Aldose reductase inhibitor, epalrestat, reduces lipid hydroperoxides in type 2 diabetes.
Topics: Adult; Aged; Aldehyde Reductase; beta Carotene; Diabetes Mellitus, Type 2; Down-Regulation; Enzyme Inhibitors; Erythrocytes; Female; Humans; Lipid Peroxidation; Lipid Peroxides; Male; Malondialdehyde; Middle Aged; Oxidative Stress; Rhodanine; Thiazolidines; Thiobarbituric Acid Reactive Substances; Vitamin E | 2009 |
1 other study(ies) available for d-alpha tocopherol and rhodanine
| Article | Year |
|---|---|
Targeted co-delivery of the aldose reductase inhibitor epalrestat and chemotherapeutic doxorubicin via a redox-sensitive prodrug approach promotes synergistic tumor suppression.
Topics: Aldehyde Reductase; Animals; Antineoplastic Agents; Doxorubicin; Drug Carriers; Drug Liberation; Drug Synergism; Enzyme Inhibitors; Female; Humans; Intracellular Space; Mice; Micelles; Oxidation-Reduction; Prodrugs; Rhodanine; Thiazolidines; Tissue Distribution; Vitamin B 6; Vitamin E | 2019 |